CanSino Biologics’ DTcP Vaccine for Infants Gains Priority Review in China
China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) announced that the New Drug Application (NDA)...
Drug
Keymed Biosciences’ Kangyueda Gains NMPA Approval for Seasonal Allergic Rhinitis
China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received another indication approval from...
Novo Nordisk’s Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference
Denmark-based Novo Nordisk A/S (NYSE: NVO) released interim results from the Phase III FRONTIER3 study,...
Biokin Pharmaceutical’s BL-M07D1 Gains NMPA Approval for Phase III Study
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that it has received approval from...
AbbVie’s Emblaveo Wins FDA Approval for Complicated Intra-Abdominal Infections
US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval from the...
Zhongsheng Pharma Gains FDA Approval for Phase II Study of RAY1225
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from...
Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306...
CanSino’s Tetanus Vaccine NDA Accepted for Review by NMPA
China-based vaccines specialist CanSino Biotechnology Inc. (HKG: 6185) announced that the National Medical Products Administration...
Huahai Pharma Set to Launch IL-17 Antibody HB0017 Clinical Study for HS
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is poised to initiate a clinical study...
Hotgen Biotech Gains NMPA Approval for AA001 Clinical Trials in Alzheimer’s Disease
China’s Hotgen Biotech Co., Ltd (SHA: 688068) announced that it has received clinical trial approval...
Merck Initiates Phase III waveLINE-010 Study for Zilovertamab Vedotin in DLBCL
US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the initiation of...
Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study
China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that it has received approval from...
Alphamab and CSPC Gain NMPA Approval for JSKN003 Phase III Trial in HER2-Positive Breast Cancer
Chinese partners Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that...
Gene Cradle’s GC310 Receives Tacit Approval from NMPA for Wilson’s Disease
Beijing-based gene therapy specialist Gene Cradle announced that it has received tacit clinical approval from...
Hanx Biopharmaceuticals Gains NMPA Approval for HX044 Clinical Trials
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clinical trial approval from...
Likang Life Sciences Gains FDA Approval for LK101 Clinical Trials
Beijing-based cell therapy developer Likang Life Sciences announced that it has received approval from the...
EMA Committee Backs Subcutaneous Rybrevant for Lung Cancer Treatment
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Akeso Completes Enrollment for Global Phase III Trial of Ivonescimab in Lung Cancer
China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the global...
Bayer Files for EMA Approval of Kerendia for Heart Failure
Bayer AG (FRA: BAYN) announced that it has made another market filing with the European...
Sino Biopharmaceutical’s Tulobuterol Patch Gains NMPA Approval
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its subsidiary Beijing Tide Pharmaceutical Co., Ltd...